STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market
STAT News · LC · trust 62/100
Vaxcyte said its experimental pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up the biotech to compete with Pfizer and Merck.
Read the original at STAT News →
Open in TruthVane →